IPSEN |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 114.4 EUR | -0.09% |
|
+1.69% | +6.02% |
| May. 02 | Ipsen Announces Executive Changes | CI |
| May. 02 | Ipsen: new President for North America | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.46B 3.72B | Sales 2025 * | 3.7B 3.98B | Capitalization | 9.46B 10.19B |
|---|---|---|---|---|---|
| Net income 2024 * | 645M 695M | Net income 2025 * | 718M 773M | EV / Sales 2024 * | 2.56 x |
| Net cash position 2024 * | 588M 634M | Net cash position 2025 * | 1.18B 1.27B | EV / Sales 2025 * | 2.24 x |
| P/E ratio 2024 * |
14.8
x | P/E ratio 2025 * |
13.3
x | Employees | 5,325 |
| Yield 2024 * |
1.05% | Yield 2025 * |
1.06% | Free-Float | 41.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipsen
More press releases
More news
| 1 week | +1.78% | ||
| Current month | +0.35% | ||
| 1 month | +5.72% | ||
| 3 months | +7.51% | ||
| 6 months | +3.25% | ||
| Current year | +6.12% |
1 week
111.40
116.40
1 month
105.30116.40
Current year
99.70116.40
1 year
99.70130.70
3 years
77.00130.70
5 years
34.20130.70
10 years
31.50155.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 55 | 14-11-02 | |
| Chairman | 66 | 10-11-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 66 | 17-06-06 |
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 65 | 15-05-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 2 M€ | +7.62% | ||
| 0.43% | 182 M€ | +5.24% | ||
| 0.31% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 114.4 | -0.09% | 5 740 |
| 24-05-03 | 114.5 | -0.52% | 42,555 |
| 24-05-02 | 115.1 | +0.88% | 55,682 |
| 24-04-30 | 114.1 | +1.42% | 77,063 |
| 24-04-29 | 112.5 | -0.44% | 77,038 |
Real-time Euronext Paris, May 06, 2024 at 07:14 am EDT
More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-05-27
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
114.5
EUR
Average target price
125.5
EUR
Spread / Average Target
+9.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.12% | 10.19B | |
| +26.08% | 662B | |
| +21.76% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 289B | |
| +13.68% | 234B | |
| +4.54% | 198B | |
| -10.59% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- IPN Stock